Skip to main content
Caplight Logo









FEMSelect

FEMSelect

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.femselect.com/

Last Round

Series B

Extension

May 13, 2025

Total Funding Raised

$14.3M

Company Overview

FEMSelect is a medical technology company that develops minimally invasive surgical systems for the treatment of pelvic organ prolapse.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

pelvic organ prolapsesurgical meshminimally invasive surgeryurogynecologypelvic floor reconstructionmedical devicesurgical systemwomen's healthPOP repairmesh-free surgerysurgical kitspelvic floor disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FEMSelect Comparables

Compare FEMSelect with similar companies based on industry and business-model similarity.

FEMSelect comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Escala Medical
92%
Neomedic International
82%
Caldera Medical
80%

FEMSelect Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 13, 2025
Series BOct 19, 2022
Series AJan 24, 2018
SeedDec 1, 2012

Key People

Founding team and executive leadership

Deborah Garner

President CEO

Executive Team

Sasha Schrode

Chief Executive Officer

Executive Team

FEMSelect Investors

Notable investors and investment history

FEMSelect investors
InvestorRounds
Nordwand CapitalSeries B Extension
TransPacific Venture PartnersSeries B
Robin Hood VenturesSeries B Extension, Series B
Keiretsu CapitalSeries B
MEDA AngelsSeries B
Keiretsu Forum Mid-AtlanticSeries B
TriventuresSeries B Extension, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors increased 41% MoM.

  • Jun 6, 2025

    Grew 25% QoQ from 12 to 15 employees.

FEMSelect Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

FEMSelect Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about FEMSelect's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range14
Year Founded2012
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?